Noticias y Actividades de Arrakis Therapeutics

Ver el organigrama con sus 18 ejecutivos principales

Biografías más buscadas en Arrakis Therapeutics

• Mark Delong, Chief Executive Officer
• Michael Gilman, Chairman of the Board
• Raj Parekh, Director

Recientes movimientos de ejecutivos en Arrakis Therapeutics

• Michael Gilman que ha sido Chief Executive Officer and Director, pasa a ser Chairman of the Board  (noticia publicada el 26 de junio de 2026).
• Mark Delong, se ha incorporado a la empresa como Chief Executive Officer  (noticia publicada el 26 de junio de 2026).
• Katrine Bosley, Chairman of its Board, ha dejado la empresa  (noticia publicada el 26 de junio de 2026).

Crear su alerta
para seguir los movimientos de los ejecutivos en Arrakis Therapeutics.

Arrakis Therapeutics tiene 2.430 competidores entre los que se incluyen Lonza (Suiza), Vertex Pharmaceuticals (Estados Unidos) y Eurofins (Luxemburgo).

Popular M&A news in Biotecnología

• Tempus has announced the acquisition of Personalis  (publicado el 20 de julio de 2026).
• Eli Lilly has announced the acquisition of AtaiBeckley  (publicado el 17 de julio de 2026).
• GSK ha Nuvalent adquirido (publicado el 17 de julio de 2026).

Otros contactos sugeridos en el sector Biotecnología

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer en Inceptive
• Jan Van de Winkel - President and Chief Executive Officer en Genmab
• Robert Gould - Board Member en Fulcrum Therapeutics

Saber más sobre el sector Biotecnología

Últimos comunicados de prensa de Arrakis Therapeutics

• Arrakis Therapeutics Announces CEO Transition with Mark DeLong Appointed as New CEO - Arrakis Therapeutics
• Arrakis Therapeutics Presents Data Highlighting Progress of Oral RNA targeted Small Molecule to Treat Myotonic Dystrophy Type 1 (DM1) - Arrakis Therapeutics
• Arrakis Therapeutics Announces Oral Presentation Describing RNA-targeted Small Molecule to Treat Myotonic Dystrophy at MDA Conference 2025 - Arrakis Therapeutics
• Arrakis Therapeutics Announces Presentations at Upcoming Scientific Meetings - Arrakis Therapeutics
• Arrakis Therapeutics Announces Presentations at Upcoming Spring Scientific Meetings - Arrakis Therapeutics
• Arrakis Therapeutics Announces Presentation of AI and Machine Learning Approaches to RNA-targeted Drug Discovery - Arrakis Therapeutics
• Jennifer Petter, Arrakis Chief Scientific Officer, is Contributing Author in Feature on Women Scientists in Journal of Medicinal Chemistry - Arrakis Therapeutics
• Arrakis Therapeutics Announces Presentations at Upcoming Fall Scientific Meetings - Arrakis Therapeutics
• Arrakis Therapeutics to Present at Jefferies Healthcare Conference - Arrakis Therapeutics
• Arrakis Therapeutics to Participate in Upcoming May Investor Conferences - Arrakis Therapeutics
• View more press releases Close

Redes sociales sobre Arrakis Therapeutics

• Arrakis Therapeutics en Wikipedia, Google News y Yahoo Finance
• Arrakis Therapeutics en LinkedIn, Twitter y YouTube